Home » Posts tagged with » Dr. Ingunn Munch Lindvig
Targovax gets FDA fast track status for ONCOS-102 in malignant pleural mesothelioma

Targovax gets FDA fast track status for ONCOS-102 in malignant pleural mesothelioma

Targovax, a Norwegian immune-oncology company, said that its lead candidate ONCOS-102 has secured the fast track designation from the US Food and Drug Administration (FDA) for malignant pleural mesothelioma. The FDA fast track status to ONCOS-102 was granted based on promising pre-clinical and clinical efficacy related to broad immune activation observed so far, said Targovax. […]